Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ludivine Douarin"'
Autor:
Marie-Laure Kürzinger, Ludivine Douarin, Ievgeniia Uzun, Chantal El-Haddad, William Hurst, Juhaeri Juhaeri, Stéphanie Tcherny-Lessenot
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 11 (2020)
A favorable benefit–risk profile remains an essential requirement for marketing authorization of medicinal drugs and devices. Furthermore, prior subjective, implicit and inconsistent ad hoc benefit–risk assessment methods have rightly evolved tow
Externí odkaz:
https://doaj.org/article/3fb28efde45540e291cfc94c60d12503
Autor:
Michael Steel, Chantal El-Haddad, Linda Härmark, Monali Desai, Ulrika Nörby, Sashka Hristoskova, Benedikte Noël-Cuppers, Ludivine Douarin
Publikováno v:
Expert Opinion on Drug Safety
Background: Inconsistencies in information on safety of medicine use during pregnancy and lactation can result in sub-optimal treatment for pregnant and lactating women, risks to the fetus or child...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38afb2b2d71595c89dfa0a0cd131fb41
https://doi.org/10.1080/14740338.2021.1935865
https://doi.org/10.1080/14740338.2021.1935865
Autor:
Marie-Laure Kürzinger, Chantal El-Haddad, Juhaeri Juhaeri, William Hurst, Ievgeniia Uzun, Stephanie Tcherny-Lessenot, Ludivine Douarin
Publikováno v:
Therapeutic Advances in Drug Safety
Therapeutic Advances in Drug Safety, Vol 11 (2020)
Therapeutic Advances in Drug Safety, Vol 11 (2020)
A favorable benefit–risk profile remains an essential requirement for marketing authorization of medicinal drugs and devices. Furthermore, prior subjective, implicit and inconsistent ad hoc benefit–risk assessment methods have rightly evolved tow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16386d2a41f0757ca56e47d988f0a888
https://pubmed.ncbi.nlm.nih.gov/33343857
https://pubmed.ncbi.nlm.nih.gov/33343857
Autor:
Linda Härmark, Ludivine Douarin, Sashka Hristoskova, Ulrika Nörby, Benedikte-Noël Cuppers, Michael Steel
Publikováno v:
Reproductive Toxicology. 97:11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::634b87b6c6d38fdd505e50342ab39c01
https://doi.org/10.1016/j.reprotox.2020.04.046
https://doi.org/10.1016/j.reprotox.2020.04.046
Autor:
Aurélie Plessier, Michel Vidaud, Dominique Valla, Marie-Hélène Denninger, Richard Moreau, Rami Moucari, Didier Lebrec, Sylvie Escolano, Pierre-Emmanuel Rautou, Raphael Itzykson, Annie Bezeaud, Ludivine Douarin
Publikováno v:
Journal of Hepatology. 54:56-63
Background & Aims Anticoagulation therapy is recommended for patients with Budd–Chiari syndrome (BCS). This study aimed to assess the incidence, severity, and risk factors of major bleeding in patients with Budd–Chiari syndrome (BCS) receiving an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27cc75e5d2493ffcfa868ed523d1cd50
https://doi.org/10.1016/j.jhep.2010.06.019
https://doi.org/10.1016/j.jhep.2010.06.019
Autor:
Aurélie Plessier, Claire Francoz, Dominique Valla, Violaine Ozenne, Rami Moucari, Ludivine Douarin, Audrey Imbert, C. Denié, Richard Moreau, Sylvie Escolano, François Durand, Didier Lebrec, Dominique Cazals–Hatem, Pierre-Emmanuel Rautou
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 7(11)
Patients with Budd-Chiari syndrome can present with acute, subacute, or chronic disease; the definitions and significance of these variants have been disputed. An increased level of serum alanine aminotransferase (ALT) is an objective marker for acut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41ab484c2cecdab0e27ee7b7d8b82902
https://pubmed.ncbi.nlm.nih.gov/19560555
https://pubmed.ncbi.nlm.nih.gov/19560555